Drug
KM-819
KM-819 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Active, not recruiting1
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
active_not_recruiting133%
terminated133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_2
A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease
NCT05670782
terminatedphase_2
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
NCT05695378
completedphase_1
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
NCT03022799
Clinical Trials (3)
Showing 3 of 3 trials
NCT05670782Phase 2
A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease
NCT05695378Phase 2
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
NCT03022799Phase 1
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3